UTMD logo

Utah Medical Products Inc

UTMD

Build a strategy around UTMD

Accountable AI Logo

Utah Medical Products Inc AI Insights

Informational only. Not investment advice.
As of 2026-01-02

Snapshot

  • Cash of 84.3M is 69% of total assets with near-zero debt (0.002 D/E) - fortress balance sheet enables full capital return flexibility[Cash and Equivalents]
  • FCF margin of 36% (13.9M TTM) on capex of just 271K - capital-light model converts nearly all operating income to cash[Free Cash Flow TTM]
  • Revenue declining 8.8% 3Y while EPS down 11.4% 3Y - shrinking business with no margin expansion to offset[Total Revenue 3Y Growth]

Watch Triggers

  • Total Revenue TTM: Quarterly revenue growth turns positiveWould signal end of multi-year decline and validate turnaround thesis
  • Cash and Equivalents: Significant decrease indicating M&A or special dividend84M cash pile deployment would signal strategic direction
  • Research and Development TTM: R&D spend increases above 3% of revenueCurrent 1.5% is insufficient for organic growth - increase signals pivot

Bull Case

Cash of 84.3M equals 46% of market cap (181M) - downside protected by liquid assets alone. EV of 97M implies core business valued at just 7x FCF.

Cash and EquivalentsEnterprise ValueFree Cash Flow TTM

Operating margin of 30.8% TTM vs industry median of 0% - exceptional profitability in niche medical devices provides durable cash generation.

Operating Margin TTMNet Margin TTM

Bear Case

Revenue down 8.8% 3Y and EPS down 19.6% 1Y - accelerating decline with minimal R&D (1.5% of sales) suggests no organic turnaround catalyst.

Total Revenue 3Y GrowthEPS Growth 1YResearch and Development TTM

Volume of 18K shares daily creates liquidity risk - difficult to build or exit meaningful positions without price impact.

Volume

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
45%

Leverage UTMD's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Revenue contraction likely to persist without M&A or new product launches

1-3ymed
  • R&D spend of 577K TTM is just 1.5% of revenue
  • 5Y revenue CAGR of -1.3% shows structural decline
  • 84M cash pile unutilized for growth initiatives
Total Revenue 5Y Growth: -1.3%R&D TTM: 577K (1.5% of sales)No acquisitions evident in cash deployment

Valuation Context

Caveats

Public Strategies Rankings

See how Utah Medical Products Inc ranks across different investment strategies.

Leverage UTMD's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.